PSA screening declines following publication of large trials, guidelines
Key points
- PSA screening has declined in one large U.S. healthcare network since publication of two large screening trials and a set of guidelines, according to a study published online February 24 in the Journal of the National Cancer Institute.
- Preventive Services Task Force issued guidelines recommending against PSA screening after age 75.
- Zeliadt, Ph.D., of the VA Puget Sound Health Care System, Seattle, and colleagues report that after publication of the trials, PSA testing declined in the U.S.
- The authors conclude that the guidelines and the trial results may have had a modest effect on PSA screening among men in the Veteran's Health Administration network.
PSA screening has declined in one large U.S. healthcare network since publication of two large screening trials and a set of guidelines, according to a study published online February 24 in the Journal of the National Cancer Institute.
In 2008, the U.S. Preventive Services Task Force issued guidelines recommending against PSA screening after age 75. The following year, investigators from two large screening trials reported contradictory results: The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial showed no difference in prostate cancer-specific mortality between screened versus non-screened men, while the European Randomized study of Screening for Prostate Cancer trial found a 20% reduction in mortality with screening.
Steven B. Zeliadt, Ph.D., of the VA Puget Sound Health Care System, Seattle, and colleagues report that after publication of the trials, PSA testing declined in the U.S. Veterans Health Administration Pacific Northwest Network. The decline was 3 percentage points among men aged 40-54; 2.7 percentage points among those aged 55-74; and 2.2 percentage points among men aged 75 years and older.
The authors conclude that the guidelines and the trial results may have had a modest effect on PSA screening among men in the Veteran's Health Administration network.
In an editorial, Siu-Long Yao, M.D., and Grace Lu-Yao, Ph.D., of the Cancer Institute of New Jersey write that it is not surprising that the effect has been only modest, given the conflicting findings of the two large trials and other studies: "When faced with data that could be interpreted as neither strongly supportive nor decidedly unfavorable, it is natural that health-care providers and their patients might not substantially alter their practices in regard to PSA screening."
###
Contacts:
Article: Jeri Rowe, Public Affairs Office, Jeri.Rowe@va.gov, (206) 764-2435
Editorial: Grace Lu-Yao; luyaogr@umdnj.edu; 732-235-8830
###
Contact: Caroline McNeil
Caroline.McNeil@oup.com
301-841-1286
Journal of the National Cancer Institute
Written and revised by
Gerald Hurowitz, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsNew Study Identifies Opportunities To Reduce Patient Burden Associated With Breast Cancer Screening
New technology and better screening strategies can lower the rate of false-positive results, which impose a substantial financial and psychological burden on women. The many misperceptions about breast cancer screening…
24 September 2014
NewsLarge study reveals new genetic variants that raise risk for prostate cancer
In an analysis of genetic information among more than 87,000 men, a global team of scientists says it has found 23 new genetic variants – common differences in the genetic code -- that increase a man's risk for prostate…
19 September 2014
NewsBreast cancer screening in over-70s 'may lead to overdiagnosis'
Involving much older women in breast cancer screening programs may "lead to overdiagnosis and overtreatment" claim experts, following a study on a Netherlands-based national program that screened women up to age 75. As…
